$TAK
AI 分析生成于 May 11, 2026
AI Score
Hold$TAK
Takeda Pharmaceutical
$TAKNYSEHealthcareLarge-Cap
Takeda develops and delivers medicines in gastroenterology, rare diseases, plasma therapies, oncology, and neuroscience.
Market Cap
$48.0B
Revenue (TTM)
$30.5B
+3.0%
Net Income (TTM)
$2.5B
+5.0%
EPS (TTM)
$1.60
P/E Ratio
20.0
Dividend Yield
4.5%
52-Week Range
$12-$18
Beta
0.52
Dimension Scores
Fundamental
66Technical
58Sentiment
62Risk / Reward
70Momentum
52Financial Health
Profitability
71moderate
Growth
55moderate
Liquidity
78strong
Solvency
68strong
Efficiency
64strong
Valuation, technical analysis, investment thesis, risk assessment and more for $TAK
Free · No credit card required
免责声明: AI 生成的分析仅供教育参考,不构成投资建议。请始终咨询合格的理财顾问。